The first GLP-1 mimetic exendin-4 (Exenatide, Byetta, and Bydureon), brought to the market to treat T2DM, showed a therapeutic effect in preclinical tests of PD [33, 37, 38]. This evidence concerns the gene GLP1R and Parkinson disease.